ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0488

Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis

Pablo Martínez Calabuig1, Elena Grau García2, Samuel Leal Rodriguez2, Ernesto Tovar Sugrañes3, José Ivorra-Cortés4, Carmen Riesco Barcena3, Anderson Huaylla Quispe3, Laura Mas Sánchez5, Pablo Muñoz Martínez6, Daniel Ramos Castro3, Alba Torrat noves7, Iago Alcantara Alvarez8, Belén Villanueva Mañés8, Miguel Simeo Vinaixa8, Andrés Pérez Hurtado3 and Jose A Román-Ivorra9, 1HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, 2HUP La Fe, Valencia, Spain, 3Rheumatology Department. HUP La Fe, Valencia, Spain, 4Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, 5Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, 6Hospital Universitario y Politècnico La Fe, Sagunto, Spain, 7Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, 8Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 9Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain

Meeting: ACR Convergence 2024

Keywords: Anti-CCP, Autoantibody(ies), rheumatoid arthritis, Rheumatoid Factor

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to the severity of the disease. Recently, anti-carbamylated protein antibodies (antiCarP) have been described as potential biomarkers for RA, especially in patients who are seronegative for traditionally evaluated antibodies.

To analyze the association of antiCarP levels with clinical activity, clinical manifestations and serological profile in RA patients

Methods: A cross-sectional observational study of patients diagnosed with RA and healthy controls (HC). A complete clinical and analytical evaluation was performed, obtaining demographic, clinical, and analytical data. The antiCarP levels were determined using ELISA.

Results: A total of 101 patients (79% female) with a mean age of 45 (13) years, and 98 HC (67% female) with a mean age of 55 (11) years were included. The patients had significantly higher antiCarP levels than HC (P< 0.001), as well as older individuals in general (P=0.004). AntiCarP levels were associated to increased RF and antiCCP levels (P< 0.001). Patients were divided into serological profiles based on the positivity of RF and antiCCP, and those RF/antiCCP positive showed a significantly high antiCarP levels compared to the rest of the groups (P< 0.001).

The cutoff value for elevated anti-CarP was established at twice the standard deviation from the average value of the HC (17.2ng/mL). 35 patients were classified as having elevated anti-CarP; 32 were included in the group with double positivity for RF/antiCCP (P=0.006), and 3 as negative for RF/antiCCP.

High antiCarP levels were associated to clinical activity as well as tender joints (P=0.001) and the presence of rheumatoid nodules and diffuse interstitial lung disease (Table). No association among antiCarp levels and Van der Heijde score, progression rate of joint damage, Raynaud’s phenomenon and Sjögren syndrome was observed.

Conclusion: RA Patients show high antiCarP levels compared to HC and especially in patients with double positivity for RF/antiCCP. The increase of antiCarP is associated to high clinical activity and high number of tender joints, as well as extraarticular manifestations of the disease.

Supporting image 1


Disclosures: P. Martínez Calabuig: None; E. Grau García: None; S. Leal Rodriguez: None; E. Tovar Sugrañes: None; J. Ivorra-Cortés: None; C. Riesco Barcena: None; A. Huaylla Quispe: None; L. Mas Sánchez: None; P. Muñoz Martínez: None; D. Ramos Castro: None; A. Torrat noves: None; I. Alcantara Alvarez: None; B. Villanueva Mañés: None; M. Simeo Vinaixa: None; A. Pérez Hurtado: None; J. Román-Ivorra: None.

To cite this abstract in AMA style:

Martínez Calabuig P, Grau García E, Leal Rodriguez S, Tovar Sugrañes E, Ivorra-Cortés J, Riesco Barcena C, Huaylla Quispe A, Mas Sánchez L, Muñoz Martínez P, Ramos Castro D, Torrat noves A, Alcantara Alvarez I, Villanueva Mañés B, Simeo Vinaixa M, Pérez Hurtado A, Román-Ivorra J. Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/association-of-anti-carp-levels-with-clinical-activity-and-serological-profile-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-anti-carp-levels-with-clinical-activity-and-serological-profile-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology